EANS-News: SYGNIS announces Financial Results for fiscal year 2009/2010

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

annual report

Heidelberg (euro adhoc) - Heidelberg, 29 June 2010 - SYGNIS Pharma AG
(Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today announced
its financial results for the 2009/2010 fiscal year, which ended on
31 March 2010.

Financial figures for the 2009/2010 fiscal year

• Cash including marketable securities was down EUR6.8 million compared
with the previous year, to EUR15.5 million. Long-term financial liabilities
amounting to EUR8.0 million resulted from a loan that will not become payable
until 2015.
• Net loss for the 2009/2010 fiscal year remains unchanged at EUR10.3
million as per the previous year.
• Operational expenditure decreased to EUR9.2 million (2008/2009: EUR11.2
million) due to lower R&D expenses.
• Financial result of -EUR1.8 million mainly due to unrealised losses on
marketable securities.

Milestones

o One of the key milestones of the reporting period is the initiation of
about 80 study centres in eight European countries to participate in the
multinational phase II efficacy study for AX200 for the treatment of acute
stroke.
o In preclinical in vivo studies SYGNIS achieved proof of concept that
enhancement of the KIBRA pathway improves cognitive functions and working
memory.
o SYGNIS made significant progress in strengthening its IP position on its
pipeline relating to AX200 as well as on the KIBRA project for drug development.

o SYGNIS secured up to EUR10 million by entering into a three year Standby
Equity Distribution Agreement (SEDA) with the US investor Yorkville Advisors.

Dr. Alfred Bach, CEO of SYGNIS Pharma, said: "SYGNIS looks back on a
busy financial year with the backdrop of a challenging global
economy. In spite of this, we achieved key milestones this year that
have enabled us to make considerable progress in our efforts for
SYGNIS´ sustainable development. In addition, we are optimistic that
we will be able to acquire new projects by licensing or M&A
transactions to extend our product and project portfolio in the near
future."

Outlook

SYGNIS expects a net loss of around EUR15 million for the current
2010/2011 fiscal year and a liquidity outflow of some EUR14 million.

The key focus for the upcoming months is the effective execution of
the ongoing multinational phase II efficacy study with AX200. Initial
results are expected to be available mid 2011. In addition, SYGNIS is
consistently searching for projects and partnerships that are in line
with its research approach and are a logical fit with the existing
portfolio. The main requirement for such projects is that they are
either already financed through to the next stage of development or
can be used to obtain new financial resources.

For the annual report for the fiscal year ended 31 March 2010 and a
presentation on SYGNIS´ annual results, please visit www.sygnis.de.

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg, is
a specialty pharmaceutical company listed on the Prime Standard of
the German stock exchange. The Company is focused on the research,
development and marketing of innovative therapies for the treatment
of disorders of the Central Nervous System. These include Stroke,
Amyotrophic Lateral Sclerosis and neurological disorders resulting
from injuries to the brain or spinal cord. All these disorders are
characterized by the fact that, as the disease progresses, nerve
cells are damaged and die. Although there is great medical demand,
there are currently no or only inadequate treatment options
available.

One of the central elements in this value-creation chain is the
continued expansion of the existing product pipeline. This is
achieved by the development of new products as a result of SYGNIS´
own research and the inorganic growth through in-licensing agreements
and acquisitions. By means of specific R&D programs at SYGNIS, new
pre-clinical drug candidates are identified and evaluated as well as
preclinical projects initiated, which are offered for inlicensing.

For further information please contact:
SYGNIS Pharma AG:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or
goals. These statements should not be considered to be total
guarantees since given their very nature they are subject to known
and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals
of SYGNIS Pharma AG may deviate greatly from the established
conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these
statements in the light of new information or future results or for
any other reason. ###

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Franz-Werner Haas

Vice President Operations

Telefon: +49(0)6221 454-812

E-Mail: franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade